We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Relaxing Restrictions on GSK’s Controversial Diabetes Drug Avandia
FDA Relaxing Restrictions on GSK’s Controversial Diabetes Drug Avandia
Three years after placing heavy restrictions on GlaxoSmithKline’s type 2 diabetes drug Avandia, the FDA said Nov. 25 it is relaxing those restrictions in line with its advisers’ recommendations.